Exendin-4,a Glucagon-Like Peptide-1 Receptor Agonist,Reduces Alzheimer Disease-Associated Tau Hyperphosphorylation in the Hippocampus of Rats with Type 2 Diabetes
Restricted accessResearch articleFirst published online February, 2015
Exendin-4,a Glucagon-Like Peptide-1 Receptor Agonist,Reduces Alzheimer Disease-Associated Tau Hyperphosphorylation in the Hippocampus of Rats with Type 2 Diabetes
Impaired insulin signaling pathway in the brain in type 2 diabetes (T2D) is a risk factor for Alzheimer disease (AD). Glucagon-like peptide-1 (GLP-1) and its receptor agonist are widely used for treatment of T2D. Here we studied whether the effects of exendin-4 (EX-4), a long-lasting GLP-1 receptor agonist, could reduce the risk of AD in T2D.
Materials and Methods
Type 2 diabetes rats were injected with EX-4 for 28 consecutive days. Blood glucose and insulin levels, as well as GLP-1 and insulin in cerebrospinal fluid, were determined during the experiment. The phosphorylation level of tau at individual phosphorylation sites, the activities of phosphatidylinositol 3 kinase/protein kinase B (PI3K/AKT), and glycogen synthase kinase-3β (GSK-3β) were analyzed with Western blots.
Results
The levels of phosphorylated tau protein at site Ser199/202 and Thr217 level in the hippocampus of T2D rats were found to be raised notably and evidently decreased after EX-4 intervention. In addition, brain insulin signaling pathway was ameliorated after EX-4 treatment, and this result was reflected by a decreased activity of PI3K/AKT and an increased activity of GSK-3β in the hippocampus of T2D rats as well as a rise in PI3K/AKT activity and a decline in GSK-3β activity after 4 weeks intervention of EX-4.
Conclusions
These results demonstrate that multiple days with EX-4 appears to prevent the hyperphosphorylation of AD-associated tau protein due to increased insulin signaling pathway in the brain. These findings support the potential use of GLP-1 for the prevention and treatment of AD in individuals with T2D.
HenryMS, PassmoreAP, ToddS, . The development of effective biomarkers for Alzheimer's disease: a review. Int J Geriatr Psychiatry. 2013; 28: 331–340.
2.
Grundke-IqbalI, IqbalK, QuinlanM, . Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986; 261: 6084–6089.
3.
Grundke-IqbalI, IqbalK, TungYC, . Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986; 83: 4913–4917.
4.
LiuF, ZaidiT, IqbalK, . Aberrant glycosylation modulates phosphorylation of tau by protein kinase and dephosphorylation of tau by protein phosphatase 2a and 5. Neuroscience. 2002; 115: 829–837.
5.
MartinL, LatypovaX, WilsonCM, . Tau protein kinases: involvement in Alzheimer's disease. Ageing Res Rev. 2013; 12: 289–309.
6.
ArriagadaPV, GrowdonJH, Hedley-WhyteET, . Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992; 42: 631–639.
7.
Gomez-IslaT, HollisterR, WestH, . Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997; 41: 17–24.
8.
DuarteAI, MoreiraPI, OliveiraCR.Insulin in central nervous system: more than just a peripheral hormone. J Aging Res. 2012; 2012: 384017.
9.
CampbellRK.Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther. 2011; 33: 511–527.
10.
HanW, LiC.Linking type 2 diabetes and Alzheimer's disease. Proc Natl Acad Sci U S A. 2010; 107: 6557–6558.
11.
KopfD, FrolichL.Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. J Alzheimers Dis. 2009; 16: 677–685.
12.
ParkSA.A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J Clin Neurol. 2011; 7: 10–18.
13.
CraftS.Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging. 2005; 26 (Suppl 1): 65–69.
14.
DuarteAI, CandeiasE, CorreiaSC, . Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochim Biophys Acta. 1832; 2013: 527–541.
15.
MoreiraPI.Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin. J Alzheimers Dis. 2012; 30 (Suppl 2): S199–S215.
16.
HoyerS.Memory function and brain glucose metabolism. Pharmacopsychiatry. 2003; 36 (Suppl 1): S62–S67.
17.
PiroliGG, GrilloCA, CharronMJ, . Biphasic effects of stress upon glut8 glucose transporter expression and trafficking in the diabetic rat hippocampus. Brain Res. 2004; 1006: 28–35.
18.
LiuY, LiuF, Grundke-IqbalI, . Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol. 2011; 225: 54–62.
19.
MoloneyAM, GriffinRJ, TimmonsS, . Defects in igf-1 receptor, insulin receptor and irs-1/2 in Alzheimer's disease indicate possible resistance to igf-1 and insulin signalling. Neurobiol Aging. 2010; 31: 224–243.
20.
JolivaltCG, LeeCA, BeiswengerKK, . Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res. 2008; 86: 3265–3274.
21.
GaoC, HolscherC, LiuY, . Gsk3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev Neurosci. 2012; 23: 1–11.
22.
MollerJB, JuskoWJ, GaoW, . Mechanism-based population modelling for assessment of l-cell function based on total glp-1 response following an oral glucose tolerance test. J Pharmacokinet Pharmacodyn. 2011; 38: 713–725.
23.
ElrickH, StimmlerL, HladCJJr, . Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964; 24: 1076–1082.
24.
DruckerDJ, NauckMA.The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368: 1696–1705.
25.
HolscherC.The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease. Alzheimers Dement. 2014; 10: S47–S54.
26.
YangY, ZhangJ, MaD, . Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. J Alzheimers Dis. 2013; 37: 637–648.
27.
HamiltonA, HolscherC.Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport. 2009; 20: 1161–1166.
28.
WilliamsDL, BaskinDG, SchwartzMW.Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology. 2009; 150: 1680–1687.
29.
HuiH, TangYG, ZhuL, . Glucagon like peptide-1-directed human embryonic stem cells differentiation into insulin-producing cells via hedgehog, camp, and pi3k pathways. Pancreas. 2010; 39: 315–322.
30.
DuringMJ, CaoL, ZuzgaDS, . Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003; 9: 1173–1179.
31.
PerryT, HaugheyNJ, MattsonMP, . Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther. 2002; 302: 881–888.
32.
McIntyreRS, PowellAM, Kaidanovich-BeilinO, . The neuroprotective effects of glp-1: possible treatments for cognitive deficits in individuals with mood disorders. Behav Brain Res. 2013; 237: 164–171.
33.
HunterK, HolscherC.Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012; 13: 33.
34.
HoistadM, SamskogJ, JacobsenKX, . Detection of beta-endorphin in the cerebrospinal fluid after intrastriatal microinjection into the rat brain. Brain Res. 2005; 1041: 167–180.
35.
MatthewsDR, HoskerJP, RudenskiAS, . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412–419.
36.
LiuY, LiuF, Grundke-IqbalI, . Brain glucose transporters, o-glcnacylation and phosphorylation of tau in diabetes and Alzheimer's disease. J Neurochem. 2009; 111: 242–249.
37.
YangY, MaD, WangY, . Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes. J Alzheimers Dis. 2013; 33: 329–338.
38.
SchuhAF, RiederCM, RizziL, . Mechanisms of brain aging regulation by insulin: implications for neurodegeneration in late-onset Alzheimer's disease. ISRN Neurol. 2011; 2011: 306905.
39.
PopkieAP, ZeidnerLC, AlbrechtAM, . Phosphatidylinositol 3-kinase (pi3k) signaling via glycogen synthase kinase-3 (gsk-3) regulates DNA methylation of imprinted loci. J Biol Chem. 2010; 285: 41337–41347.
40.
HerrmannN, ChauSA, KircanskiI, . Current and emerging drug treatment options for Alzheimer's disease: a systematic review. Drugs. 2011; 71: 2031–2065.
41.
GongCX, Grundke-IqbalI, IqbalK.Targeting tau protein in Alzheimer's disease. Drugs Aging. 2010; 27: 351–365.
42.
de la MonteSM.Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res. 2012; 9: 35–66.
43.
AbbasT, FaivreE, HolscherC.Impairment of synaptic plasticity and memory formation in glp-1 receptor ko mice: interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res. 2009; 205: 265–271.
44.
YangY, HuS, ZhangJ, . Alzheimer-like hyperphosphorylation of tau in brains of rats with obesity and type 2 diabetes. Prog Biochem Biophys. 2006; 33: 458–464.
